You are here: Industry Insights > Neurological diseases

News List

Navigating the Neurodegenerative Crisis: A Multifaceted Approach Shruti Talashi
December 09, 2024
Overtaking more established issues like cancer and heart disease, neurological problems have become a major worldwide health concern.
Zepp Health Invests $2.4M to Lead neuro42's Series A Round prnasia
July 28, 2021
Zepp Health Corp., and neuro42, Inc. today announced that Zepp Health is investing $2.4 million to lead the $6.5 million Series A funding round for the development of MRI and robotics technology that allows physicians to diagnose brain injury in acute ...
New breakthrough could help us understand how rare childhood brain disorders develop expresspharma
April 29, 2020
Findings by researchers from the University of Sheffield reveal that defective immune cells in the brain contribute to the development of rare neurological diseases that cause severe physical and mental disabilities in children.
Biogen, Sangamo team up on neurological diseases pharmatimes
March 06, 2020
Biogen and Sangamo have unveiled plans to collaborate on a new global licensing agreement to develop and commercialise ST-501 for tauopathies including Alzheimer’s disease, and other neurological diseases.
Survey shows efficacy of BoNT-A treatment for spasticity pharmaceutical-technology
January 21, 2019
An international survey conducted by biopharmaceutical group Ipsen and social media platform Carenity found a significant hidden burden associated with spasticity and 94% satisfaction with ....
Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech roles pharmaphorum
January 17, 2019
Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZeneca.
Biogen signs two deals to address neurological disorders pharmaceutical-technology
January 08, 2019
Biogen has signed a strategic collaboration with US-based drug maker C4 Therapeutics for the discovery and development of new therapies to treat neurological diseases, including Alzheimer’s disease.....
Proteome blood test developer Seer emerges with $36M in funding fiercebiotech
December 26, 2018
Seer, a liquid biopsy company aimed at querying the body’s proteome, has emerged from stealth with $36 million in funding to develop early-warning tests for cancer and neurological diseases.
Neurological diseases cost the US nearly $800 billion per year worldpharmanews
March 30, 2017
A new paper published in the Annals of Neurology reports the most common neurological diseases pose a serious annual financial burden for the nation.